3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Cytarabine
6
Thioguanine
4
Methotrexate
4
Idarubicin
4
Etoposide
4
Daunorubicin
4
Azacitidine
4
Peripheral Blood Stem Cell Transplantation
3
Early Intervention, Educational
3
Decitabine
3
Cyclophosphamide
3
liposomal amphotericin B
2
decitabine and cedazuridine drug combination
2
Therapeutics
2
Radiotherapy
2
Psychiatric Rehabilitation
2
ON 01910
2
Mitoxantrone
2
Hydrocortisone
2
Filgrastim
2
Dexamethasone
2
Busulfan
2
Biopsy
2
Asparaginase
2
valspodar
1
sabatolimab
1
pevonedistat
1
palmitoyl-L-asparaginase
1
merphos
1
lonafarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myelomonocytic, Chronic
×
sabatolimab
×
Clear all
NCT04266301
2026-01-13
STIMULUS-MDS2
Novartis
Phase 3
Terminated
530 enrolled
29 charts